Page 13 - CUA Adv Prostate Ca Drug Acccess Listing

A BC Cancer Compassionate Access Program request must be approved prior to treatment. 2. BC Cancer
1
Restricted funding* Protocol
2
UGUPENZ [8-
Eligibility : 21]
1,2
• mCRPC 3. BC Cancer
• Chemotherapy-naïve or received prior chemotherapy containing docetaxel Benefit Drug
Not • ECOG PS 0-2 List [9-21]
mCRPC Tablet
specified • Life expectancy > 3 months

Patients can receive either enzalutamide or apalutamide or abiraterone but not sequential use
of these agents.

Exclusions :
2
• Uncontrolled hypertension (systolic BP > 160 mmHg or diastolic BP > 95 mmHg)
A BC Cancer Compassionate Access Program request must be approved prior to treatment. 1. BC Cancer
1
Enzalutamide Restricted funding* Protocol
2
(Xtandi) UGUNMPENZ
Astellas Eligibility : [8-21]
1
• nmCRPC 2. BC Cancer
• No radiologic evidence of metastases (negative bone scan, negative CT of pelvis, Benefit Drug
abdomen, chest) List [9-21]
• Chemotherapy-naïve
• ECOG PS 0-2
nmCRPC Tablet Not • PSADT ≤ 10 months
specified

Patients with nmCRPC may receive one of apalutamide, darolutamide or enzalutamide, but
not their sequential use.
Patients who progressed on enzalutamide in nmCRPC are eligible to receive docetaxel and/or
cabazitaxel in mCRPC, but are not eligible to receive enzalutamide or abiraterone in mCRPC.
1
Exclusions :
• mCRPC
• Prior treatment with apalutamide or darolutamide in nmCRPC
• Uncontrolled hypertension (systolic BP > 160 mmHg or diastolic BP > 95 mmHg)

mCSPC - - No listing as of Sep. 2021
Olaparib
(Lynparza) mCRPC - - No listing for prostate cancer as of Sep. 2021
AstraZeneca
*Restricted funding is reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide
the appropriate clinical information for each patient.

Page 7 | © Canadian Urological Association
v.01-SEP-2021